N-Terminal Pro-Brain Natriuretic Peptide and Cardiorenal Outcome in Patients with Anaemia in Chronic Kidney Disease

Figure 1. Association of baseline blood N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) level and cardiovascular outcome. (A) A restricted spline curve representing the hazard ratio for cardiovascular outcomes in relation to baseline NT‐proBNP level is shown. The hazard ratio is depicted in two lines: one unadjusted (blue line) and the other adjusted for various factors, including age, sex, body mass index, smoking history, hypertension, ischaemic heart disease, previous heart failure hospitalization, renin–angiotensin system inhibitor use, sympatholytic drug use, diuretic use, primary kidney disease, estimated glomerular filtration rate, and haemoglobin and ferritin level at 12 weeks (red line). NT‐proBNP levels are shown on a logarithmic scale. (B) A Kaplan–Meier curve illustrating the cumulative incidence of cardiovascular outcomes among patients with baseline NT‐proBNP of <250 pg/mL (red line), NT‐proBNP of 250–500 pg/mL (blue line), NT‐proBNP of 500–1000 pg/mL (green line) and NT‐proBNP of ≥1000 pg/mL (purple line).

Figure 2. Initial 12 week change in blood N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) level and cardiovascular outcome. The incidence of cardiovascular outcomes is presented as a bar graph, with participants divided into subgroups based on their first 12 week haemoglobin level change (tertile) and baseline NT‐proBNP levels (quintile).

Figure 3. Association of the baseline blood N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) level and renal outcome. (A) A restricted spline curve illustrating the hazard ratio for renal outcomes relative to baseline NT‐proBNP levels. The hazard ratio is depicted in two lines: one unadjusted (blue line) and the other adjusted for various factors, including age, sex, body mass index, smoking history, hypertension, ischaemic heart disease, previous heart failure hospitalization, renin–angiotensin system inhibitor use, sympatholytic drug use, diuretic use, primary kidney disease, estimated glomerular filtration rate, and haemoglobin and ferritin level at 12 weeks (red line). NT‐proBNP levels are shown on a logarithmic scale. (B) A Kaplan–Meier curve illustrating the cumulative incidence of renal outcomes among patients with baseline NT‐proBNP of <250 pg/mL (red line), NT‐proBNP of 250–500 pg/mL (blue line), NT‐proBNP of 500–1000 pg/mL (green line) and NT‐proBNP of ≥1000 pg/mL (purple line).

Figure 4. Initial 12 week change in blood N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) level and renal outcome. The incidence of renal outcomes is shown as a bar graph, with participants divided into subgroups based on their first 12 week haemoglobin level change (tertile) and the baseline NT‐proBNP level (quintile).